Home/Pipeline/IL23R program

IL23R program

Psoriasis

Pre-clinicalHit-to-Lead

Key Facts

Indication

Psoriasis

Phase

Pre-clinical

Status

Hit-to-Lead

Company

Acellera

About Acellera

Acellera's mission is to transform drug discovery into a high-accuracy, computable task by developing algorithms that automate the process. Founded in 2016, the company has built a robust technology stack, including the QuantumBind® platform and open-source tools like ACEMD, OpenMM, and ACEGEN, backed by over 18 years of computational know-how and thousands of academic citations. While currently a private company with no external investment, Acellera is developing an internal pipeline of drug candidates and plans to raise funding in 2026 to scale its ambitious goals.

View full company profile

Therapeutic Areas

Oncology Immunology Inflammatory Diseases Infectious Diseases Neurology

Other Psoriasis Drugs

Drug	Company	Phase	Status
Autoimmune psoriasis candidate	Nyrada	Preclinical	Active
CYPS317	FibroBiologics	Discovery	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
Undisclosed Psoriasis Program	Nepsone	Preclinical	Active
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
TEM-1657 (Oral)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
Laikangqita Monoclonal Antibody	Livzon Pharmaceutical	NDA	Marketing application accepted and granted priority review
CT-P55	Celltrion	Phase 3	Active
JNJ-77242113	Johnson & Johnson	Phase 3	Active